- Home
- PLUR vs CGTX Comparison
PLUR vs CGTX Comparison
Compare PLUR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- CGTX
- Stock Information
- Founded
- PLUR 2001
- CGTX 2007
- Country
- PLUR Israel
- CGTX United States
- Employees
- PLUR N/A
- CGTX N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- CGTX Health Care
- Exchange
- PLUR Nasdaq
- CGTX Nasdaq
- Market Cap
- PLUR 44.7M
- CGTX 53.4M
- IPO Year
- PLUR N/A
- CGTX 2021
- Fundamental
- Price
- PLUR $5.17
- CGTX $2.43
- Analyst Decision
- PLUR Strong Buy
- CGTX Strong Buy
- Analyst Count
- PLUR 1
- CGTX 3
- Target Price
- PLUR $12.00
- CGTX $2.83
- AVG Volume (30 Days)
- PLUR 13.3K
- CGTX 11.9M
- Earning Date
- PLUR 09-17-2025
- CGTX 08-07-2025
- Dividend Yield
- PLUR N/A
- CGTX N/A
- EPS Growth
- PLUR N/A
- CGTX N/A
- EPS
- PLUR N/A
- CGTX N/A
- Revenue
- PLUR $1,034,000.00
- CGTX N/A
- Revenue This Year
- PLUR $395.40
- CGTX N/A
- Revenue Next Year
- PLUR $186.32
- CGTX N/A
- P/E Ratio
- PLUR N/A
- CGTX N/A
- Revenue Growth
- PLUR 203.23
- CGTX N/A
- 52 Week Low
- PLUR $3.33
- CGTX $0.22
- 52 Week High
- PLUR $7.13
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- PLUR 52.68
- CGTX 63.80
- Support Level
- PLUR $4.75
- CGTX $2.62
- Resistance Level
- PLUR $5.68
- CGTX $3.83
- Average True Range (ATR)
- PLUR 0.36
- CGTX 0.45
- MACD
- PLUR 0.03
- CGTX 0.08
- Stochastic Oscillator
- PLUR 65.41
- CGTX 53.29
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.